Mediwound Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Mediwound Ltd (MDWD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Mediwound Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 17M vs 751M combined for tracked competitors (2.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-49.8%) for its tracked peer group.
- Growth: Mediwound Ltd generated -16.1% revenue growth year over year in Q4 2025, vs 22.8% for its tracked competitors combined.
- Profitability: Its -140.8% net margin compares with 10.3% for the peer group.
- Scale: Mediwound Ltd ranks #10 of 37 companies by market capitalization in the Legal Cannabis industry, holding 1.5% of industry market cap.
- Peer revenue share: Mediwound Ltd accounted for 15.2% of combined revenue among its tracked peer group, down from 20.9% a year earlier.
- Peer differentiation: Revenue per employee of $2.42M compares with $1.58M for the peer group (1.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MDWD Sales vs. its Competitors, Q4 2025
Mediwound Ltd reported revenue contraction of 16.14 % year on year in Q4 2025, below its competitors' combined revenue growth of 22.79 %.
With a net margin of -140.80 %, Mediwound Ltd reported lower profitability than its competitors (10.30 %).
Mediwound Ltd generated 15.24 % of the combined sales of its peer group, down from 20.85 % a year earlier.
Mediwound Ltd vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Mediwound Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Mediwound Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Mediwound Ltd's competitor groups requires a Commercial License.
For context: the Legal Cannabis industry grew revenue 35.0% year over year, combined, vs -16.1% for Mediwound Ltd. Mediwound Ltd's share of combined industry revenue moved from 0.85% to 0.53%, a loss of 0.32 percentage points.
Mediwound Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Mediwound Ltd | - | No | No | No |
| Competitors combined (5) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDWD Stock Performance relative to its Competitors
MDWD Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Vericel Corporation | 282.9% | Outperformed |
| 2 | Biocardia Inc | 282.9% | Outperformed |
| 3 | United Health Products Inc | 282.9% | Outperformed |
| 4 | Heartbeam Inc | 282.9% | Outperformed |
| 5 | Plus Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Mediwound Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Mediwound Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Mediwound Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Mediwound Ltd | 158.48 | 16.96 |
| Vericel Corporation | 2,105.03 | 306.30 |
| Plus Therapeutics Inc | 26.48 | 4.20 |
| Heartbeam Inc | 19.69 | 438.83 |
| Biocardia Inc | 12.58 | 1.33 |
| United Health Products Inc | 9.75 | 0.00 |
| SUBTOTAL | 2,332.00 | 767.62 |
Sources: Mediwound Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Mediwound Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Mediwound Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Vericel Corporation | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Mediwound Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Mediwound Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Mediwound Ltd | 158 | 2,422,714 | -3,411,286 |
| Vericel Corporation | 2,105 | 769,606 | 60,857 |
| Plus Therapeutics Inc | 26 | 150,107 | -931,714 |
| Heartbeam Inc | 20 | 25,813,471 | -1,193,882 |
| Biocardia Inc | 13 | 63,095 | -349,476 |
| United Health Products Inc | 10 | 41 | -142,248 |
| PEERS TOTAL | 2,174 | 1,583,672 | -65,242 |
Mediwound Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 24 companies in Mediwound Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Mediwound Ltd ranks #10 of 24 companies by market capitalization in its industry, holding 1.46 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,412, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 3,966 | 37.16 % |
| 2 | Regencell Bioscience Holdings Limited | 3,076 | 28.82 % |
| 3 | Cronos Group Inc | 1,262 | 11.82 % |
| 4 | Tilray Brands Inc | 454 | 4.25 % |
| 5 | Canopy Growth Corporation | 1,234 | 5.2% |
| 6 | Sndl Inc | 1,234 | 5.2% |
| 7 | Usana Health Sciences Inc | 1,234 | 5.2% |
| 8 | Niagen Bioscience Inc | 1,234 | 5.2% |
| 9 | Aurora Cannabis Inc | 1,234 | 5.2% |
| 10 | Mediwound Ltd | 156 | 1.46 % |
Market cap and industry share for the rest of Mediwound Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Mediwound Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 5 | Canopy Growth Corporation | 393 | -32.01 % |
| 6 | Sndl Inc | 351 | -43.15 % |
| 7 | Usana Health Sciences Inc | 271 | -48.18 % |
| 8 | Niagen Bioscience Inc | 246 | -68.28 % |
| 9 | Aurora Cannabis Inc | 1,234 | 12.3% |
| 10 | Mediwound Ltd | 156 | -22.71 % |
| 11 | Fitlife Brands Inc | 1,234 | 12.3% |
| 12 | Upexi Inc | 1,234 | 12.3% |
| 13 | Charlie s Holdings Inc | 1,234 | 12.3% |
| 14 | Biote Corp | 1,234 | 12.3% |
| 15 | China Foods Holdings Ltd | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Mediwound Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Mediwound Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Legal Cannabis industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (36 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 19.19 % | 38.25 % (avg) | -19.1 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -0.49 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 32.46 % | 3.73 % (avg) | +28.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Mediwound Ltd's Valuation vs Competitive Position
Valuation multiples vs the Legal Cannabis industry average (36 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 18.3x | - |
| EV / EBITDA | - | 7.2x | - |
| P/B | 4.8x | 5.5x | -0.7x |
| Return on Equity | -54.73 % | industry aggregate | 0.06 % |
| Return on Invested Capital | -17.09 % | 3.55 % (avg) | -20.64 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Mediwound Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -29.48 % | 8.22 % | -16.14 % |
| Operating Margin | -81.83 % | -95.94 % | - |
| Return on Invested Capital | -12.87 % | -17.76 % | -17.09 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Mediwound Ltd's BCG Growth-Share Matrix
Relative market share (vs Mediwound Ltd's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Mediwound Ltd falls in the Dog quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 2.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Definium Therapeutics Inc alone holds 37% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Mediwound Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 2,412 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 32.46 % vs industry average 3.73 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Mediwound Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Mediwound Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Mediwound Ltd's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Mediwound Ltd falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Mediwound Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.04x).
Opportunities
No rule matched.
Threats
- Industry dominated by Definium Therapeutics Inc , holding 37.16 % of industry market cap.
- Tracked peer group's revenue run-rate is broadly decelerating (-49.8% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Mediwound Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Mediwound Ltd | 0.19 | 2.33 | - |
| Vericel Corporation | 2.24 | 5.03 | - |
| Plus Therapeutics Inc | 0.65 | 1.47 | 0.05 |
| Heartbeam Inc | 1.48 | 1.59 | - |
| Biocardia Inc | 1.22 | 1.28 | - |
| United Health Products Inc | 0.00 | 0.02 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Mediwound Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Mediwound Ltd | Q4 2025 | -16.1 % | - |
| Vericel Corporation | Q2 2026 | +22.5 % | - |
| Plus Therapeutics Inc | Q2 2026 | -70.4 % | - |
| Heartbeam Inc | Q2 2026 | - | - |
| Biocardia Inc | Q2 2026 | - | - |
| United Health Products Inc | Q2 2026 | - | - |
| PEERS TOTAL | +7.9 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Mediwound Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Mediwound Ltd | Q4 2025 | -12.6 % | -12.2 % |
| Vericel Corporation | Q2 2026 | +26.6 % | -76.2 % |
| Plus Therapeutics Inc | Q2 2026 | - | +7,028.6 % |
| Heartbeam Inc | Q2 2026 | - | +144.1 % |
| Biocardia Inc | Q2 2026 | - | - |
| United Health Products Inc | Q2 2026 | - | - |
Mediwound Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Mediwound Ltd | - | - | - |
| Vericel Corporation | 5.02% | 5.58% | 6.91% |
| Plus Therapeutics Inc | - | - | - |
| Heartbeam Inc | - | - | - |
| Biocardia Inc | - | - | - |
| United Health Products Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Mediwound Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Mediwound Ltd | - | 9.34 |
| Vericel Corporation | 85.62 | 6.87 |
| Plus Therapeutics Inc | - | 6.30 |
| Heartbeam Inc | - | 0.04 |
| Biocardia Inc | - | 9.49 |
| United Health Products Inc | - | 23,726.33 |
| PEERS AVERAGE | - | 3.04 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.